{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T16:38:23Z","timestamp":1789749503165,"version":"4.0.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T00:00:00Z","timestamp":1739145600000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dermatol Ther (Heidelb)"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s13555-024-01325-7","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T15:50:39Z","timestamp":1739202639000},"page":"395-411","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Analysis of Predefined Safety Events Across Spesolimab Trials in Dermatological and Non-Dermatological Conditions"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9347-0292","authenticated-orcid":false,"given":"Kenneth B.","family":"Gordon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3743-135X","authenticated-orcid":false,"given":"Yayoi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0723-3953","authenticated-orcid":false,"given":"Milan J.","family":"Anadkat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7796-5746","authenticated-orcid":false,"given":"Siew Eng","family":"Choon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1475-2874","authenticated-orcid":false,"given":"Boni","family":"Elewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9030-183X","authenticated-orcid":false,"given":"Jonathan N.","family":"Barker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6084-5617","authenticated-orcid":false,"given":"Arash","family":"Mostaghimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0094-2674","authenticated-orcid":false,"given":"Kilian","family":"Eyerich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6451-8648","authenticated-orcid":false,"given":"Ming","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Haeufel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0967-2028","authenticated-orcid":false,"given":"Christian","family":"Thoma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8513-550X","authenticated-orcid":false,"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"issue":"4","key":"1325_CR1","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1111\/jdv.18851","volume":"37","author":"L Puig","year":"2023","unstructured":"Puig L, Choon SE, Gottlieb AB, et al. Generalized pustular psoriasis: a global Delphi consensus on clinical course, diagnosis, treatment goals and disease management. J Eur Acad Dermatol Venereol. 2023;37(4):737\u201352.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"1","key":"1325_CR2","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.jaci.2016.08.056","volume":"140","author":"A Johnston","year":"2017","unstructured":"Johnston A, Xing X, Wolterink L, et al. IL-1 and IL-36 are dominant cytokines in generalized pustular psoriasis. J Allergy Clin Immunol. 2017;140(1):109\u201320.","journal-title":"J Allergy Clin Immunol"},{"issue":"26","key":"1325_CR3","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1056\/NEJMoa2111563","volume":"385","author":"H Bachelez","year":"2021","unstructured":"Bachelez H, Choon S-E, Marrakchi S, et al. Trial of spesolimab for generalized pustular psoriasis. N Engl J Med. 2021;385(26):2431\u201340.","journal-title":"N Engl J Med"},{"issue":"10412","key":"1325_CR4","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1016\/S0140-6736(23)01378-8","volume":"402","author":"A Morita","year":"2023","unstructured":"Morita A, Strober B, Burden AD, et al. Efficacy and safety of subcutaneous spesolimab for the prevention of generalised pustular psoriasis flares (Effisayil 2): an international, multicentre, randomised, placebo-controlled trial. Lancet. 2023;402(10412):1541\u201351.","journal-title":"Lancet"},{"key":"1325_CR5","unstructured":"Boehringer Ingelheim Pharmaceuticals, Inc. SPEVIGO\u00ae (spesolimab-sbzo) prescribing information. Ridgefield, CT. March 2024."},{"key":"1325_CR6","unstructured":"SPEVIGO\u00ae (spesolimab-sbzo). Annex I: summary of product characteristics. Boehringer Ingelheim International GmbH. Ingelheim am Rhein, Germany. December 2022."},{"key":"1325_CR7","unstructured":"Boehringer Ingelheim (China) Investment Co. Ltd. Package insert of spesolimab injection (intravenous formulation). Shanghai, China. December 2022."},{"key":"1325_CR8","unstructured":"Boehringer Ingelheim (China) Investment Co. Ltd. Package insert of spesolimab injection (subcutaneous injection). Shanghai, China. March 2024."},{"issue":"4","key":"1325_CR9","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1016\/j.jaci.2021.09.035","volume":"149","author":"P Baum","year":"2022","unstructured":"Baum P, Visvanathan S, Garcet S, et al. Pustular psoriasis: molecular pathways and effects of spesolimab in generalized pustular psoriasis. J Allergy Clin Immunol. 2022;149(4):1402\u201312.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"1325_CR10","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/j.jaci.2019.11.047","volume":"145","author":"LC Tsoi","year":"2020","unstructured":"Tsoi LC, Rodriguez E, St\u00f6lzl D, et al. Progression of acute-to-chronic atopic dermatitis is associated with quantitative rather than qualitative changes in cytokine responses. J Allergy Clin Immunol. 2020;145(5):1406\u201315.","journal-title":"J Allergy Clin Immunol"},{"issue":"12","key":"1325_CR11","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1111\/jdv.14389","volume":"31","author":"R Thomi","year":"2017","unstructured":"Thomi R, Kakeda M, Yawalkar N, Schlapbach C, Hunger RE. Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa. J Eur Acad Dermatol Venereol. 2017;31(12):2091\u20136.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"1325_CR12","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1080\/14712598.2020.1695775","volume":"20","author":"C Neufert","year":"2020","unstructured":"Neufert C, Neurath MF, Atreya R. Rationale for IL-36 receptor antibodies in ulcerative colitis. Expert Opin Biol Ther. 2020;20(4):339\u201342.","journal-title":"Expert Opin Biol Ther"},{"issue":"2","key":"1325_CR13","doi-asserted-by":"publisher","DOI":"10.1172\/JCI144336","volume":"131","author":"M Elias","year":"2021","unstructured":"Elias M, Zhao S, Le HT, et al. IL-36 in chronic inflammation and fibrosis - bridging the gap? J Clin Invest. 2021;131(2):e144336.","journal-title":"J Clin Invest"},{"issue":"2","key":"1325_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s13555-021-00504-0","volume":"11","author":"U Mrowietz","year":"2021","unstructured":"Mrowietz U, Burden AD, Pinter A, et al. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with palmoplantar pustulosis: results of a phase\u00a0IIa, multicenter, double-blind, randomized, placebo-controlled pilot study. Dermatol Ther (Heidelb). 2021;11(2):571\u201385.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"10","key":"1325_CR15","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1007\/s13555-023-01002-1","volume":"13","author":"AD Burden","year":"2023","unstructured":"Burden AD, Bissonnette R, Navarini AA, et al. Spesolimab efficacy and safety in patients with moderate-to-severe palmoplantar pustulosis: a multicentre, double-blind, randomised, placebo-controlled, phase\u00a0IIb, dose-finding study. Dermatol Ther (Heidelb). 2023;13(10):2279\u201397.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"3","key":"1325_CR16","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1111\/jdv.18727","volume":"37","author":"R Bissonnette","year":"2023","unstructured":"Bissonnette R, Abramovits W, Saint-Cyr Proulx \u00c9, et al. Spesolimab, an anti-interleukin-36 receptor antibody, in patients with moderate-to-severe atopic dermatitis: results from a multicentre, randomized, double-blind, placebo-controlled, phase\u00a0IIa study. J Eur Acad Dermatol Venereol. 2023;37(3):549\u201357.","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"1325_CR17","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/bjd\/ljae144","volume":"1919","author":"A Alavi","year":"2024","unstructured":"Alavi A, Prens E, Kimball AB, et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled clinical trial. Br J Dermatol. 2024;1919:508\u201318.","journal-title":"Br J Dermatol"},{"issue":"2","key":"1325_CR18","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1080\/14740338.2022.2103536","volume":"22","author":"M Ferrante","year":"2023","unstructured":"Ferrante M, Irving PM, Selinger CP, et al. Safety and tolerability of spesolimab in patients with ulcerative colitis. Expert Opin Drug Saf. 2023;22(2):141\u201352.","journal-title":"Expert Opin Drug Saf"},{"key":"1325_CR19","unstructured":"ClinicalTrials.gov. A study testing how BI 655130 works in patients with fistulizing Crohn's disease 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03752970."},{"key":"1325_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j895","volume":"356","author":"RJ Desai","year":"2017","unstructured":"Desai RJ, Bateman BT, Huybrechts KF, et al. Risk of serious infections associated with use of immunosuppressive agents in pregnant women with autoimmune inflammatory conditions: cohort study. BMJ. 2017;356:j895.","journal-title":"BMJ"},{"issue":"2","key":"1325_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1007\/s13555-024-01103-5","volume":"14","author":"T Bhutani","year":"2024","unstructured":"Bhutani T, Farberg AS. Clinical and disease burden of patients with generalized pustular psoriasis: a review of real-world evidence. Dermatol Ther (Heidelb). 2024;14(2):341\u201360.","journal-title":"Dermatol Ther (Heidelb)"},{"issue":"4","key":"1325_CR22","doi-asserted-by":"publisher","first-page":"740","DOI":"10.3390\/vaccines11040740","volume":"11","author":"F Bellinato","year":"2023","unstructured":"Bellinato F, Gisondi P, Marzano AV, et al. Characteristics of patients experiencing a flare of generalized pustular psoriasis: a multicenter observational study. Vaccines (Basel). 2023;11(4):740.","journal-title":"Vaccines (Basel)"},{"issue":"5","key":"1325_CR23","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1111\/bjd.12501","volume":"169","author":"SH Kardaun","year":"2013","unstructured":"Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. Br J Dermatol. 2013;169(5):1071\u201380.","journal-title":"Br J Dermatol"},{"key":"1325_CR24","unstructured":"ClinicalTrials.gov. Effisayil\u2122 ON: a study to test long-term treatment with spesolimab in people with generalized pustular psoriasis who took part in a previous study 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03886246."},{"key":"1325_CR25","unstructured":"ClinicalTrials.gov. A study investigating long-term treatment with spesolimab in people with a skin disease called hidradenitis suppurativa who completed a previous clinical trial 2023. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04876391."},{"key":"1325_CR26","unstructured":"ClinicalTrials.gov. A study to test whether spesolimab helps people with generalized pustular psoriasis (GPP) who need treatment for repeated flares 2024. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06013969."},{"issue":"6","key":"1325_CR27","first-page":"753","volume":"20","author":"K Reich","year":"2022","unstructured":"Reich K, Augustin M, Gerdes S, et al. Generalized pustular psoriasis: overview of the status quo and results of a panel discussion. J Dtsch Dermatol Ges. 2022;20(6):753\u201371.","journal-title":"J Dtsch Dermatol Ges"},{"issue":"6","key":"1325_CR28","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s40264-021-01065-z","volume":"44","author":"R Bissonnette","year":"2021","unstructured":"Bissonnette R, Gottlieb AB, Langley RG, et al. Signal detection and methodological limitations in a real-world registry: learnings from the evaluation of long-term safety analyses in PSOLAR. Drug Saf. 2021;44(6):699\u2013709.","journal-title":"Drug Saf"},{"key":"1325_CR29","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1186\/s41927-019-0094-3","volume":"3","author":"CT Ritchlin","year":"2019","unstructured":"Ritchlin CT, Stahle M, Poulin Y, et al. Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics. BMC Rheumatol. 2019;3:52.","journal-title":"BMC Rheumatol"},{"issue":"9","key":"1325_CR30","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1001\/jamadermatol.2015.0718","volume":"151","author":"RE Kalb","year":"2015","unstructured":"Kalb RE, Fiorentino DF, Lebwohl MG, et al. Risk of serious infection with biologic and systemic treatment of psoriasis: results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). JAMA Dermatol. 2015;151(9):961\u20139.","journal-title":"JAMA Dermatol"}],"updated-by":[{"DOI":"10.1007\/s13555-025-01372-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T00:00:00Z","timestamp":1743811200000}}],"container-title":["Dermatology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13555-024-01325-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13555-024-01325-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T16:11:51Z","timestamp":1744733511000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13555-024-01325-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["1325"],"URL":"https:\/\/doi.org\/10.1007\/s13555-024-01325-7","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s13555-025-01372-8","asserted-by":"object"}]},"ISSN":["2193-8210","2190-9172"],"issn-type":[{"value":"2193-8210","type":"print"},{"value":"2190-9172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"22 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13555-025-01372-8","URL":"https:\/\/doi.org\/10.1007\/s13555-025-01372-8","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Kenneth B Gordon reports grant support and consulting fees from AbbVie, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, Novartis, and UCB, and has received consulting fees from Amgen, Almirall, Dermira, LEO Pharma, Pfizer, and Sun Pharmaceutical Industries. Yayoi Tada declares receiving honoraria and\/or grants from AbbVie, Boehringer Ingelheim, Eisai, Eli Lilly, Janssen, Kyowa Kirin, LEO Pharma, Maruho, Mitsubishi Tanabe Pharma, Novartis, Sun Pharmaceutical Industries, Taiho Pharmaceutical, Torii Pharmaceutical, and UCB. Milan J Anadkat declares paid activities as a current advisor or consultant for Biolinq, Boehringer Ingelheim, Eli Lilly, Novocure, Protagonist Therapeutics, Kintara, Evommune, and SpringWorks Therapeutics; has served as a prior consultant or advisor for AbbVie, Adgero Pharmaceuticals, Amgen, Aspire Bariatrics, AstraZeneca, Biogen, Bristol Myers Squibb, ImClone Systems, Innovaderm Research, OnQuality Pharmaceuticals, Therakos, Veloce BioPharma, and UCB; and has served as an investigator for AbbVie, AnaptysBio, Biogen, Boehringer Ingelheim, ChemoCentryx, Eli Lilly, InCyte, InflaRx, Hana Biosciences, Hoth, Lutris, MoonLake, Novartis, OnQuality Pharmaceuticals, Regeneron, Sanofi, UCB, Veloce BioPharma, XBiotech, and Xoma. Siew Eng Choon declares paid activities as an advisor, speaker, or consultant for AbbVie, Almirall, Boehringer Ingelheim, Eli Lilly, Janssen, LEO Pharma, MSD, Novartis, Pfizer, Sanofi, and UCB. Boni Elewski has received research grants (paid to institution) from AbbVie, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Ortho Dermatology, Pfizer, and UCB; and is a consultant for Amgen (previously Celgene), Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Janssen, LEO Pharma, Novartis, Ortho Dermatology, and UCB. Jonathan N Barker has received honoraria and\/or research grants from AbbVie, Almirall, Amgen, AnaptysBio, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Eli Lilly, Janssen, LEO\u00a0Pharma, Novartis, Samsung, and Sun Pharmaceutical Industries. Kilian Eyerich declares having attended advisory boards and\/or received speaker fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, Incyte, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi, and UCB. Arash Mostaghimi has received consulting fees from Abbvie, ACOM Health, Bioniz, Boehringer Ingelheim, Concert, Digital Diagnostics, Eli Lilly, Equillium, Hims & Hers Health, and Pfizer; equity from ACOM Health, Figure 1, and Hims & Hers Health; licensing\/royalties from Concert and Pfizer; and research funding from Aclaris, Concert, Eli Lilly, and Incyte. Ming Tang, Thomas Haeufel, and Christian Thoma are employees of Boehringer Ingelheim. Diamant Tha\u00e7i has served as a consultant, advisory board member, and\/or investigator for AbbVie, Almirall, Amgen, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Celltrion, Eli Lilly, Janssen-Cilag, LEO Pharma, L\u2019Oreal, New Bridge, Novartis, Pfizer, Regeneron, Sanofi, Sun Pharmaceutical Industries, and UCB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The trials were conducted in accordance with the trial protocol, the International Council for Harmonisation Good Clinical Practice guidelines, Regulation No. 536\/2014 (EU [European Union]), the Japanese Good Clinical Practice regulations, and applicable local regulations. The studies were approved by ethics committees of participating institutions and countries. The authors acknowledge that the original studies obtained the necessary patient consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}